2014
DOI: 10.1128/jvi.02725-13
|View full text |Cite
|
Sign up to set email alerts
|

Presence of Viral DNA in Whole-Genome Sequencing of Brain Tumor Tissues from The Cancer Genome Atlas

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
1
1

Year Published

2015
2015
2021
2021

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 12 publications
(11 citation statements)
references
References 5 publications
0
9
1
1
Order By: Relevance
“…Nevertheless, this approach also failed to identify any meaningful virus associations in the analyzed samples. This is in contrast to a report by Amirian et al in which they identified HHV-6A and HHV-6B in the WGS datasets from TCGA [ 5 ]. Another study conducted by Cimino et al also identified HHV-6 and EBV DNA when they analyzed unmapped reads from a NGS-based comprehensive oncology panel [ 9 ].…”
Section: Discussioncontrasting
confidence: 99%
“…Nevertheless, this approach also failed to identify any meaningful virus associations in the analyzed samples. This is in contrast to a report by Amirian et al in which they identified HHV-6A and HHV-6B in the WGS datasets from TCGA [ 5 ]. Another study conducted by Cimino et al also identified HHV-6 and EBV DNA when they analyzed unmapped reads from a NGS-based comprehensive oncology panel [ 9 ].…”
Section: Discussioncontrasting
confidence: 99%
“…Most of this debate stems from the fact that different research groups, often using different assays, have generated evidence to support or refute the presence of HCMV in GBM tumors. There is a large amount of research supporting both sides of this issue (Amirian, Bondy, Mo, Bainbridge, & Scheurer, 2014; Baryawno et al, 2011; Baumgarten et al, 2014; Cosset et al, 2014; Fornara et al, 2016; Hashida et al, 2015; Holdhoff et al, 2015; Joseph, McDermott, Baryshnikova, Cobbs, & Ulasov, 2017; Khoury et al, 2013; Lehrer, Green, Rosenzweig, & Rendo, 2015; Libard et al, 2014; McFaline-Figueroa & Wen, 2017; Prins, Cloughesy, & Liau, 2008; Rahbar et al, 2012; Sardi et al, 2015; Schelhorn et al, 2013; Shamran et al, 2015; Solomon, Ramkissoon, Milner, & Folkerth, 2014; Stangherlin et al, 2016; Strong et al, 2016; Wolmer-Solberg et al, 2013) that we summarize in Fig. 1B–D.…”
Section: Introductionmentioning
confidence: 90%
“…The advantage of this technology is that a higher coverage of the target region and thus detection of rare variants is achieved. By means of PCR, BEAMing, and targeted NGS, known (point) mutations can be detected while whole genome or whole exome sequencing may identify unknown mutations, chromosomal aberrations, and altered numbers of copies as well as viral DNA sequences and their integration sites in the human genome 240 . Disadvantages of NGS technology for application in this routine are still the high costs, the precondition of high-quality DNA as well as the abundance of generated data that have to be analyzed and interpreted.…”
Section: Follow-upmentioning
confidence: 99%